Furthermore, we provided in vitro data declaring the anti-proliferation efficacy of MK2 inhibitor IV in MM cells and gained further insights to determine whether MK2 inhibitor is more effective than monotherapeutic agent (such as bortezomib, doxorubicin, or dexamethasone). The gene discussed is MAPKAPK2; the disease is Miyoshi myopathy.